BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver diseases. Gut. 2009;58:704-720. [PMID: 19359436 DOI: 10.1136/gut.2008.156307] [Cited by in Crossref: 225] [Cited by in F6Publishing: 226] [Article Influence: 17.3] [Reference Citation Analysis]
Number Citing Articles
1 Doycheva I, Leise MD, Watt KD. The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know. Transplantation. 2016;100:61-68. [PMID: 26647107 DOI: 10.1097/tp.0000000000001008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
2 Gehrke N, Garcia-Bardon D, Mann A, Schad A, Alt Y, Wörns MA, Sprinzl MF, Zimmermann T, Menke J, Engstler AJ, Bergheim I, He YW, Galle PR, Schuchmann M, Schattenberg JM. Acute organ failure following the loss of anti-apoptotic cellular FLICE-inhibitory protein involves activation of innate immune receptors. Cell Death Differ 2015;22:826-37. [PMID: 25342470 DOI: 10.1038/cdd.2014.178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
3 Chang WT, Cheng HL, Hsieh BS, Chiu CC, Lee KT, Chang KL. Progesterone increases apoptosis and inversely decreases autophagy in human hepatoma HA22T/VGH cells treated with epirubicin. ScientificWorldJournal 2014;2014:567148. [PMID: 24971383 DOI: 10.1155/2014/567148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
4 Lau E, Carvalho D, Freitas P. Gut Microbiota: Association with NAFLD and Metabolic Disturbances. Biomed Res Int. 2015;2015:979515. [PMID: 26090468 DOI: 10.1155/2015/979515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
5 Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711. [PMID: 21292470 DOI: 10.1016/j.jnutbio.2010.10.002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 117] [Article Influence: 10.3] [Reference Citation Analysis]
6 Doi H, Hayashi E, Arai J, Tojo M, Morikawa K, Eguchi J, Ito T, Kanto T, Kaplan DE, Yoshida H. Enhanced B-cell differentiation driven by advanced cirrhosis resulting in hyperglobulinemia. J Gastroenterol Hepatol 2018. [PMID: 29427373 DOI: 10.1111/jgh.14123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4:391-417. [PMID: 22043231 DOI: 10.1177/1756283x11413002] [Cited by in Crossref: 141] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
8 Wang Y, Ziogas DC, Biddinger S, Kokkotou E. You deserve what you eat: lessons learned from the study of the melanin-concentrating hormone (MCH)-deficient mice. Gut 2010;59:1625-34. [PMID: 20966023 DOI: 10.1136/gut.2010.210526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Zhao HW, Zhang ZF, Chai X, Li GQ, Cui HR, Wang HB, Meng YK, Liu HM, Wang JB, Li RS, Bai ZF, Xiao XH. Oxymatrine attenuates CCl4-induced hepatic fibrosis via modulation of TLR4-dependent inflammatory and TGF-β1 signaling pathways. Int Immunopharmacol 2016;36:249-55. [PMID: 27179304 DOI: 10.1016/j.intimp.2016.04.040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
10 Nezi V, Deutsch M, Gazouli M, Alexopoulou A, Paparrigopoulos T, Liappas IA, Dourakis SP. Polymorphisms of the CD14 genes are associated with susceptibility to alcoholic liver disease in Greek patients. Alcohol Clin Exp Res. 2013;37:244-251. [PMID: 23009036 DOI: 10.1111/j.1530-0277.2012.01925.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
11 Getachew A, Abbas N, You K, Yang Z, Hussain M, Huang X, Cheng Z, Tan S, Tao J, Yu X, Chen Y, Yang F, Pan T, Xu Y, Xu G, Zhuang Y, Wu F, Li Y. SAA1/TLR2 axis directs chemotactic migration of hepatic stellate cells responding to injury. iScience 2021;24:102483. [PMID: 34113824 DOI: 10.1016/j.isci.2021.102483] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Kessoku T, Kobayashi T, Tanaka K, Yamamoto A, Takahashi K, Iwaki M, Ozaki A, Kasai Y, Nogami A, Honda Y, Ogawa Y, Kato S, Imajo K, Higurashi T, Hosono K, Yoneda M, Usuda H, Wada K, Saito S, Nakajima A. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. Int J Mol Sci 2021;22:8161. [PMID: 34360923 DOI: 10.3390/ijms22158161] [Reference Citation Analysis]
13 Liu X, Huang K, Zhang RJ, Mei D, Zhang B. Isochlorogenic Acid A Attenuates the Progression of Liver Fibrosis Through Regulating HMGB1/TLR4/NF-κB Signaling Pathway. Front Pharmacol 2020;11:582. [PMID: 32425800 DOI: 10.3389/fphar.2020.00582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
14 Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology 2012;143:1158-72. [PMID: 22982943 DOI: 10.1053/j.gastro.2012.09.008] [Cited by in Crossref: 387] [Cited by in F6Publishing: 369] [Article Influence: 38.7] [Reference Citation Analysis]
15 Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31:213-221. [PMID: 26212089 DOI: 10.1111/jgh.13058] [Cited by in Crossref: 70] [Cited by in F6Publishing: 72] [Article Influence: 11.7] [Reference Citation Analysis]
16 Park DW, Lee HK, Jeong TW, Kim JS, Bae YS, Chin BR, Baek SH. The JAK2-Akt-glycogen synthase kinase-3β signaling pathway is involved in toll-like receptor 2-induced monocyte chemoattractant protein-1 regulation. Mol Med Rep 2012;5:1063-7. [PMID: 22218715 DOI: 10.3892/mmr.2012.741] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
17 Lin A, Wang G, Zhao H, Zhang Y, Han Q, Zhang C, Tian Z, Zhang J. TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells. Oncoimmunology. 2015;5:e1074376. [PMID: 27057441 DOI: 10.1080/2162402x.2015.1074376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
18 Park BJ, Lee YJ, Lee HR. Chronic liver inflammation: Clinical implications beyond alcoholic liver disease. World J Gastroenterol 2014; 20(9): 2168-2175 [PMID: 24605015 DOI: 10.3748/wjg.v20.i9.2168] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
19 Kang JW, Yoon SJ, Sung YK, Lee SM. Magnesium chenoursodeoxycholic acid ameliorates carbon tetrachloride-induced liver fibrosis in rats. Exp Biol Med (Maywood) 2012;237:83-92. [PMID: 22185916 DOI: 10.1258/ebm.2011.011219] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
20 Raso GM, Simeoli R, Iacono A, Santoro A, Amero P, Paciello O, Russo R, D’Agostino G, Di Costanzo M, Canani RB. Effects of a Lactobacillus paracasei B21060 based synbiotic on steatosis, insulin signaling and toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 2014;25:81-90. [PMID: 24314869 DOI: 10.1016/j.jnutbio.2013.09.006] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
21 Wei X, Liu H, Li X, Liu X. Over-expression of MiR-122 promotes apoptosis of hepatocellular carcinoma via targeting TLR4. Ann Hepatol 2019;18:869-78. [PMID: 31477445 DOI: 10.1016/j.aohep.2019.07.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 Manco M, Putignani L, Bottazzo GF. Gut Microbiota, Lipopolysaccharides, and Innate Immunity in the Pathogenesis of Obesity and Cardiovascular Risk. Endocrine Reviews 2010;31:817-44. [DOI: 10.1210/er.2009-0030] [Cited by in Crossref: 268] [Cited by in F6Publishing: 262] [Article Influence: 22.3] [Reference Citation Analysis]
23 Wen Z, Ji X, Tang J, Lin G, Xiao L, Liang C, Wang M, Su F, Ferrandon D, Li Z. Positive Feedback Regulation between Transglutaminase 2 and Toll-Like Receptor 4 Signaling in Hepatic Stellate Cells Correlates with Liver Fibrosis Post Schistosoma japonicum Infection. Front Immunol 2017;8:1808. [PMID: 29321784 DOI: 10.3389/fimmu.2017.01808] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
24 Getachew A, Hussain M, Huang X, Li Y. Toll-like receptor 2 signaling in liver pathophysiology. Life Sci 2021;284:119941. [PMID: 34508761 DOI: 10.1016/j.lfs.2021.119941] [Reference Citation Analysis]
25 Filliol A, Piquet-Pellorce C, Raguénès-Nicol C, Dion S, Farooq M, Lucas-Clerc C, Vandenabeele P, Bertrand MJM, Le Seyec J, Samson M. RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis. J Hepatol 2017;66:1205-13. [PMID: 28088582 DOI: 10.1016/j.jhep.2017.01.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
26 Alisi A, Manco M, Devito R, Nobili V. Fatty Liver Disease. In: Freemark M, editor. Pediatric Obesity. New York: Springer; 2010. pp. 201-22. [DOI: 10.1007/978-1-60327-874-4_15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Li L, Chen L, Hu L, Liu Y, Sun HY, Tang J, Hou YJ, Chang YX, Tu QQ, Feng GS. Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 2011;54:1620-1630. [PMID: 21809356 DOI: 10.1002/hep.24552] [Cited by in Crossref: 146] [Cited by in F6Publishing: 148] [Article Influence: 13.3] [Reference Citation Analysis]
28 Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord. 2019;20:461-472. [PMID: 31707624 DOI: 10.1007/s11154-019-09512-0] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 49.5] [Reference Citation Analysis]
29 Yuan Y, Han Q, Li S, Tian Z, Zhang J. Wnt2b attenuates HSCs activation and liver fibrosis through negative regulating TLR4 signaling. Sci Rep 2017;7:3952. [PMID: 28638086 DOI: 10.1038/s41598-017-04374-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
30 Kabilova TO, Kovtonyuk LV, Zonov EV, Ryabchikova EI, Popova NA, Nikolin VP, Kaledin VI, Zenkova MA, Vlassov VV, Chernolovskaya EL. Immunotherapy of hepatocellular carcinoma with small double-stranded RNA. BMC Cancer 2014;14:338. [PMID: 24886485 DOI: 10.1186/1471-2407-14-338] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
31 Gao B. Innate immunity and steatohepatitis: a critical role of another toll (TLR-9). Gastroenterology. 2010;139:27-30. [PMID: 20639084 DOI: 10.1053/j.gastro.2010.05.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
32 Williams JB, Hüppner A, Mulrooney-Cousins PM, Michalak TI. Differential Expression of Woodchuck Toll-Like Receptors 1-10 in Distinct Forms of Infection and Stages of Hepatitis in Experimental Hepatitis B Virus Infection. Front Microbiol 2018;9:3007. [PMID: 30581424 DOI: 10.3389/fmicb.2018.03007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
33 Lu WN, Feng LY. Role of gut microbiota in pathogenesis of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2014; 22(3): 340-344 [DOI: 10.11569/wcjd.v22.i3.340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Xiang M, Fan J, Fan J. Association of Toll-like receptor signaling and reactive oxygen species: a potential therapeutic target for posttrauma acute lung injury. Mediators Inflamm 2010;2010:916425. [PMID: 20706658 DOI: 10.1155/2010/916425] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
35 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol 2020;5:996-1007. [PMID: 32805205 DOI: 10.1016/S2468-1253(20)30216-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
36 Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68:280-295. [PMID: 29154964 DOI: 10.1016/j.jhep.2017.11.014] [Cited by in Crossref: 257] [Cited by in F6Publishing: 247] [Article Influence: 51.4] [Reference Citation Analysis]
37 Soares JB, Pimentel-Nunes P, Afonso L, Rolanda C, Lopes P, Roncon-Albuquerque R, Gonçalves N, Boal-Carvalho I, Pardal F, Lopes S. Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. Innate Immun. 2012;18:700-708. [PMID: 22330637 DOI: 10.1177/1753425912436762] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
38 Li X, Yao Q, Huang J, Jin Q, Xu B, Chen F, Tu C. Morin Hydrate Inhibits TREM-1/TLR4-Mediated Inflammatory Response in Macrophages and Protects Against Carbon Tetrachloride-Induced Acute Liver Injury in Mice. Front Pharmacol 2019;10:1089. [PMID: 31616301 DOI: 10.3389/fphar.2019.01089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
39 Iruzubieta P, Terán &, Crespo J, Fábrega E. Vitamin D deficiency in chronic liver disease. World J Hepatol 2014; 6(12): 901-915 [PMID: 25544877 DOI: 10.4254/wjh.v6.i12.901] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
40 Jaeschke H. DAMPen danger signals: novel therapeutic strategies against postischemic inflammation. Crit Care Med 2010;38:998-9. [PMID: 20168165 DOI: 10.1097/CCM.0b013e3181cc13e2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC, Bergheim I. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr. 2012;107:1727-1738. [PMID: 22018861 DOI: 10.1017/s0007114511004983] [Cited by in Crossref: 84] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
42 Song IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, Yang L, Seki E. The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice. Int J Cancer. 2018;142:81-91. [PMID: 28875549 DOI: 10.1002/ijc.31029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
43 Suraweera DB, Weeratunga AN, Hu RW, Pandol SJ, Hu R. Alcoholic hepatitis: The pivotal role of Kupffer cells. World J Gastrointest Pathophysiol 2015; 6(4): 90-98 [PMID: 26600966 DOI: 10.4291/wjgp.v6.i4.90] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
44 Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S, Gérard P, Zhao L. Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease. mBio 2020;11:e03263-19. [PMID: 32019793 DOI: 10.1128/mBio.03263-19] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
45 Grainger J, Daw R, Wemyss K. Systemic instruction of cell-mediated immunity by the intestinal microbiome. F1000Res 2018;7:F1000 Faculty Rev-1910. [PMID: 30631436 DOI: 10.12688/f1000research.14633.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
46 Molina MF, Abdelnabi MN, Fabre T, Shoukry NH. Type 3 cytokines in liver fibrosis and liver cancer. Cytokine 2019;124:154497. [DOI: 10.1016/j.cyto.2018.07.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
47 Senkerikova R, de Mare-bredemeijer E, Frankova S, Roelen D, Visseren T, Trunecka P, Spicak J, Metselaar H, Jirsa M, Kwekkeboom J, Sperl J. Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation. Journal of Hepatology 2014;60:773-81. [DOI: 10.1016/j.jhep.2013.12.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Bataller R, Rombouts K, Altamirano J, Marra F. Fibrosis in alcoholic and nonalcoholic steatohepatitis. Best Practice & Research Clinical Gastroenterology 2011;25:231-44. [DOI: 10.1016/j.bpg.2011.02.010] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
49 Li X, Jin Q, Yao Q, Xu B, Li Z, Tu C. Quercetin attenuates the activation of hepatic stellate cells and liver fibrosis in mice through modulation of HMGB1-TLR2/4-NF-κB signaling pathways. Toxicol Lett 2016;261:1-12. [PMID: 27601294 DOI: 10.1016/j.toxlet.2016.09.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
50 Wu H, Pang H, Chen Y, Huang L, Liu H, Zheng Y, Sun C, Zhang G, Wang G. Anti-Inflammatory Effect of a Polyphenol-Enriched Fraction from Acalypha wilkesiana on Lipopolysaccharide-Stimulated RAW 264.7 Macrophages and Acetaminophen-Induced Liver Injury in Mice. Oxid Med Cell Longev 2018;2018:7858094. [PMID: 30159118 DOI: 10.1155/2018/7858094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
51 Zhang W, Wang LW, Wang LK, Li X, Zhang H, Luo LP, Song JC, Gong ZJ. Betaine protects against high-fat-diet-induced liver injury by inhibition of high-mobility group box 1 and Toll-like receptor 4 expression in rats. Dig Dis Sci. 2013;58:3198-3206. [PMID: 23861108 DOI: 10.1007/s10620-013-2775-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
52 El-Bendary M, Naemattalah M, Yassen A, Mousa N, Elhammady D, Sultan AM, Abdel-Wahab M. Interrelationship between Toll-like receptors and infection after orthotopic liver transplantation. World J Transplant 2020; 10(6): 162-172 [PMID: 32742949 DOI: 10.5500/wjt.v10.i6.162] [Reference Citation Analysis]
53 Chen Y, Sun R. Toll-like receptors in acute liver injury and regeneration. Int Immunopharmacol. 2011;11:1433-1441. [PMID: 21601014 DOI: 10.1016/j.intimp.2011.04.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
54 Eiró N, Altadill A, Juárez LM, Rodríguez M, González LO, Atienza S, Bermúdez S, Fernandez-Garcia B, Fresno-Forcelledo MF, Rodrigo L. Toll-like receptors 3, 4 and 9 in hepatocellular carcinoma: Relationship with clinicopathological characteristics and prognosis. Hepatol Res. 2014;44:769-778. [PMID: 23742263 DOI: 10.1111/hepr.12180] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
55 Ceccarelli S, Nobili V, Alisi A. Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. World J Gastroenterol. 2014;20:16443-16451. [PMID: 25469012 DOI: 0.3748/wjg.v20.i44.16443] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Xiang M, Fan J. Pattern recognition receptor-dependent mechanisms of acute lung injury. Mol Med 2010;16:69-82. [PMID: 19949486 DOI: 10.2119/molmed.2009.00097] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 4.7] [Reference Citation Analysis]
57 Jose SS, Bendickova K, Kepak T, Krenova Z, Fric J. Chronic Inflammation in Immune Aging: Role of Pattern Recognition Receptor Crosstalk with the Telomere Complex? Front Immunol 2017;8:1078. [PMID: 28928745 DOI: 10.3389/fimmu.2017.01078] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
58 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
59 Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol. 2010;7:425-436. [PMID: 20585339 DOI: 10.1038/nrgastro. 2010.97] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Chiu CC, Ching YH, Li YP, Liu JY, Huang YT, Huang YW, Yang SS, Huang WC, Chuang HL. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients 2017;9:E1220. [PMID: 29113135 DOI: 10.3390/nu9111220] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
61 Luong KV, Nguyen LT. The role of vitamin d in autoimmune hepatitis. J Clin Med Res. 2013;5:407-415. [PMID: 24171052 DOI: 10.4021/jocmr1505w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
62 Diniz AB, Antunes MM, Lacerda VAS, Nakagaki BN, Freitas Lopes MA, Castro-Oliveira HM, Mattos MS, Mafra K, de Miranda CDM, de Oliveira Costa KM, Lopes ME, Alvarenga DM, Carvalho-Gontijo R, Marchesi SC, Lacerda DR, de Araújo AM, de Carvalho É, David BA, Santos MM, Lima CX, Silva Gomes JA, Minto Fontes Cal TC, de Souza BR, Couto CA, Faria LC, Teixeira Vidigal PV, Matos Ferreira AV, Radhakrishnnan S, Ricci M, Oliveira AG, Rezende RM, Menezes GB. Imaging and immunometabolic phenotyping uncover changes in the hepatic immune response in the early phases of NAFLD. JHEP Rep 2020;2:100117. [PMID: 32695965 DOI: 10.1016/j.jhepr.2020.100117] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Feng W, Gu YF, Nie L, Guo DY, Xiang LX, Shao JZ. Characterization of SIGIRR/IL-1R8 Homolog from Zebrafish Provides New Insights into Its Inhibitory Role in Hepatic Inflammation. J Immunol 2016;197:151-67. [PMID: 27206770 DOI: 10.4049/jimmunol.1502334] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
64 Zheng Q, Martin RC, Shi X, Pandit H, Yu Y, Liu X, Guo W, Tan M, Bai O, Meng X, Li Y. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics 2020;10:9923-36. [PMID: 32929325 DOI: 10.7150/thno.45988] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
65 Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J Gastroenterol 2014; 20(47): 17756-17772 [PMID: 25548474 DOI: 10.3748/wjg.v20.i47.17756] [Cited by in CrossRef: 184] [Cited by in F6Publishing: 166] [Article Influence: 23.0] [Reference Citation Analysis]
66 Wang Y, Liu Y, Kirpich I, Ma Z, Wang C, Zhang M, Suttles J, McClain C, Feng W. Lactobacillus rhamnosus GG reduces hepatic TNFα production and inflammation in chronic alcohol-induced liver injury. J Nutr Biochem. 2013;24:1609-1615. [PMID: 23618528 DOI: 10.1016/j.jnutbio.2013.02.001] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 9.9] [Reference Citation Analysis]
67 Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med. 2012;10:151. [PMID: 22846613 DOI: 10.1186/1479-5876-10-151] [Cited by in Crossref: 107] [Cited by in F6Publishing: 99] [Article Influence: 10.7] [Reference Citation Analysis]
68 Piñero P, Juanola O, Caparrós E, Zapater P, Giménez P, González-Navajas JM, Such J, Francés R. Toll-like receptor polymorphisms compromise the inflammatory response against bacterial antigen translocation in cirrhosis. Sci Rep 2017;7:46425. [PMID: 28418003 DOI: 10.1038/srep46425] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
69 Center SA, Randolph JF, Warner KL, McDonough SP, Lucy JM, Sapa KC. Bacterial culture and immunohistochemical detection of bacteria and endotoxin in cats with suppurative cholangitis-cholangiohepatitis syndrome. J Am Vet Med Assoc 2021;:1-18. [PMID: 34936576 DOI: 10.2460/javma.20.10.0552] [Reference Citation Analysis]
70 Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5(10): 528-540 [PMID: 24179612 DOI: 10.4254/wjh.v5.i10.528] [Cited by in Crossref: 123] [Cited by in F6Publishing: 118] [Article Influence: 13.7] [Reference Citation Analysis]
71 Modena KCDS, Calvo AM, Sipert CR, Dionísio TJ, Navarro MFL, Atta MT, Santos CF. Dental Pulp Fibroblasts Response after Stimulation with HEMA and Adhesive System. Braz Dent J 2018;29:419-26. [PMID: 30517439 DOI: 10.1590/0103-6440201802558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 Stärkel P, De Saeger C, Strain AJ, Leclercq I, Horsmans Y. NFkappaB, cytokines, TLR 3 and 7 expression in human end-stage HCV and alcoholic liver disease. Eur J Clin Invest. 2010;40:575-584. [PMID: 20658750 DOI: 10.1111/j.1365-2362.2010.02295.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
73 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269. [PMID: 23394092 DOI: 10.2174/1381612811399990344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Roh YS, Cho A, Cha YS, Oh SH, Lim CW, Kim B. Lactobacillus Aggravate Bile Duct Ligation-Induced Liver Inflammation and Fibrosis in Mice. Toxicol Res 2018;34:241-7. [PMID: 30057698 DOI: 10.5487/TR.2018.34.3.241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Khalsa J, Duffy LC, Riscuta G, Starke-reed P, Hubbard VS. Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine. Clinical Pharmacology in Drug Development 2017;6:176-85. [DOI: 10.1002/cpdd.310] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
76 Tsujimoto T, Kawaratani H, Kitazawa T, Uemura M, Fukui H. Innate immune reactivity of the ileum-liver axis in nonalcoholic steatohepatitis. Dig Dis Sci. 2012;57:1144-1151. [PMID: 22367065 DOI: 10.1007/s10620-012-2073-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
77 Remus DM, Kleerebezem M, Bron PA. An intimate tête-à-tête — How probiotic lactobacilli communicate with the host. European Journal of Pharmacology 2011;668:S33-42. [DOI: 10.1016/j.ejphar.2011.07.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
78 McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 2014;60:1055-62. [PMID: 24445215 DOI: 10.1016/j.jhep.2014.01.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
79 Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 2016; 8(32): 1354-1369 [PMID: 27917262 DOI: 10.4254/wjh.v8.i32.1354] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
80 Miranda-Díaz AG, Alonso-Martínez H, Hernández-Ojeda J, Arias-Carvajal O, Rodríguez-Carrizalez AD, Román-Pintos LM. Toll-like receptors in secondary obstructive cholangiopathy. Gastroenterol Res Pract. 2011;2011:265093. [PMID: 22114589 DOI: 10.1155/2011/265093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
81 Molina PE, Gardner JD, Souza-Smith FM, Whitaker AM. Alcohol abuse: critical pathophysiological processes and contribution to disease burden. Physiology (Bethesda) 2014;29:203-15. [PMID: 24789985 DOI: 10.1152/physiol.00055.2013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
82 Nakamura H, Henderson D, Puri P. A meta-analysis of clinical outcome of intestinal transplantation in patients with total intestinal aganglionosis. Pediatr Surg Int. 2017;33:837-841. [PMID: 28600659 DOI: 10.1007/s00383-017-4107-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
83 Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13:397-402. [PMID: 20531177 DOI: 10.1097/MCO.0b013e32833aae84] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
84 Bleau C, Burnette M, Filliol A, Piquet-Pellorce C, Samson M, Lamontagne L. Toll-like receptor-2 exacerbates murine acute viral hepatitis. Immunology 2016;149:204-24. [PMID: 27273587 DOI: 10.1111/imm.12627] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
85 Ilan Y. Leaky gut and the liver: A role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18(21): 2609-2618 [PMID: 22690069 DOI: 10.3748/wjg.v18.i21.2609] [Cited by in CrossRef: 112] [Cited by in F6Publishing: 104] [Article Influence: 11.2] [Reference Citation Analysis]
86 Kirpich IA, Feng W, Wang Y, Liu Y, Barker DF, Barve SS, McClain CJ. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res. 2012;36:835-846. [PMID: 22150547 DOI: 10.1111/j.1530-0277.2011.01673.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
87 Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. [PMID: 30213667 DOI: 10.1016/j.mam.2018.09.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 127] [Article Influence: 30.3] [Reference Citation Analysis]
88 Wang X, Xia J, Jiang C. Role of gut microbiota in the development of non-alcoholic fatty liver disease. Liver Research 2019;3:25-30. [DOI: 10.1016/j.livres.2019.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Lee W, Lee SH, Kim M, Moon JS, Kim GW, Jung HG, Kim IH, Oh JE, Jung HE, Lee HK, Ku KB, Ahn DG, Kim SJ, Kim KS, Oh JW. Vibrio vulnificus quorum-sensing molecule cyclo(Phe-Pro) inhibits RIG-I-mediated antiviral innate immunity. Nat Commun 2018;9:1606. [PMID: 29686409 DOI: 10.1038/s41467-018-04075-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
90 Lopes JAG, Borges-Canha M, Pimentel-Nunes P. Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis? World J Hepatol 2016; 8(3): 162-182 [PMID: 26839640 DOI: 10.4254/wjh.v8.i3.162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
91 Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Königsrainer A, Bischoff SC, Bergheim I. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2015;35:562-568. [PMID: 24351080 DOI: 10.1111/liv.12442] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
92 Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010;7:425-36. [DOI: 10.1038/nrgastro.2010.97] [Cited by in Crossref: 377] [Cited by in F6Publishing: 379] [Article Influence: 31.4] [Reference Citation Analysis]
93 Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus. 2015;24:469-482. [PMID: 25801890 DOI: 10.1177/0961203314556140] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
94 Li R, Mao Z, Ye X, Zuo T. Human Gut Microbiome and Liver Diseases: From Correlation to Causation. Microorganisms 2021;9:1017. [PMID: 34066850 DOI: 10.3390/microorganisms9051017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Gan N, Yang L, Omran A, Peng J, Wu L, He F, Zhang C, Xiang Q, Kong H, Ma Y, Ashhab MU, Deng X, Yin F. Myoloid-Related Protein 8, an Endogenous Ligand of Toll-Like Receptor 4, Is Involved in Epileptogenesis of Mesial Temporal Lobe Epilepsy Via Activation of the Nuclear Factor-κB Pathway in Astrocytes. Mol Neurobiol 2014;49:337-51. [DOI: 10.1007/s12035-013-8522-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
96 Ruess DA, Probst M, Marjanovic G, Wittel UA, Hopt UT, Keck T, Bausch D. HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury. PLoS One 2016;11:e0161233. [PMID: 27513861 DOI: 10.1371/journal.pone.0161233] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
97 Kanak MA, Shindo Y, Saikumar P, Naziruddin B. Role of Inflammasomes in the Development of Gastrointestinal Diseases. In: Cordero MD, Alcocer-gómez E, editors. Inflammasomes: Clinical and Therapeutic Implications. Cham: Springer International Publishing; 2018. pp. 235-68. [DOI: 10.1007/978-3-319-89390-7_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Wu L, Sun J, Liu L, Du X, Liu Y, Yan X, Kombo Osoro E, Zhang F, Feng L, Liang D, Li Y, Chen Q, Sun S, Zhang L, Lan X, Li D, Lu S. Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways. Int Immunopharmacol 2020;82:106368. [PMID: 32151955 DOI: 10.1016/j.intimp.2020.106368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
99 Liu WT, Jing YY, Han ZP, Li XN, Liu Y, Lai FB, Li R, Zhao QD, Wu MC, Wei LX. The injured liver induces hyperimmunoglobulinemia by failing to dispose of antigens and endotoxins in the portal system. PLoS One. 2015;10:e0122739. [PMID: 25826264 DOI: 10.1371/journal.pone.0122739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
100 Chen EB, Cason C, Gilbert JA, Ho KJ. Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. J Gastrointest Surg 2018;22:1112-23. [PMID: 29623674 DOI: 10.1007/s11605-018-3755-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
101 Qian H, Shi J, Fan TT, Lv J, Chen SW, Song CY, Zheng ZW, Xie WF, Chen YX. Sophocarpine attenuates liver fibrosis by inhibiting the TLR4 signaling pathway in rats. World J Gastroenterol 2014; 20(7): 1822-1832 [PMID: 24587659 DOI: 10.3748/wjg.v20.i7.1822] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
102 Martrus G, Goebels H, Langeneckert AE, Kah J, Flomm F, Ziegler AE, Niehrs A, Löbl SM, Russu K, Hess LU, Salzberger W, Poch T, Nashan B, Schramm C, Oldhafer KJ, Dandri M, Koch M, Lunemann S, Altfeld M. CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans. Front Immunol 2019;10:1247. [PMID: 31231382 DOI: 10.3389/fimmu.2019.01247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
103 Takashima S, Ikejima K, Arai K, Yokokawa J, Kon K, Yamashina S, Watanabe S. Glycine prevents metabolic steatohepatitis in diabetic KK-A y mice through modulation of hepatic innate immunity. American Journal of Physiology-Gastrointestinal and Liver Physiology 2016;311:G1105-13. [DOI: 10.1152/ajpgi.00465.2015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
104 Zayed RA, Omran D, Mokhtar DA, Zakaria Z, Ezzat S, Soliman MA, Mobarak L, El-Sweesy H, Emam G. Association of Toll-Like Receptor 3 and Toll-Like Receptor 9 Single Nucleotide Polymorphisms with Hepatitis C Virus Infection and Hepatic Fibrosis in Egyptian Patients. Am J Trop Med Hyg 2017;96:720-6. [PMID: 28093541 DOI: 10.4269/ajtmh.16-0644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
105 Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int J Mol Sci 2020;21:E8351. [PMID: 33171747 DOI: 10.3390/ijms21218351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
106 Sevastianos VA, Voulgaris TA, Dourakis SP. Hepatitis C, systemic inflammation and oxidative stress: correlations with metabolic diseases. Expert Review of Gastroenterology & Hepatology 2020;14:27-37. [DOI: 10.1080/17474124.2020.1708191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
107 Zhang T, Sun K, Wang Y, Huang L, Lang R, Jiang W. Disruption of the gut-liver axis in the pathogenesis of acute-on-chronic liver failure. Eur J Gastroenterol Hepatol 2018;30:130-5. [PMID: 29200007 DOI: 10.1097/MEG.0000000000001026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
108 Yuan Z, Yuan Z, Hasnat M, Zhang H, Liang P, Sun L, Jiang Z, Zhang L. A new perspective of triptolide-associated hepatotoxicity: the relevance of NF- κ B and NF- κ B-mediated cellular FLICE-inhibitory protein. Acta Pharm Sin B 2020;10:861-77. [PMID: 32528833 DOI: 10.1016/j.apsb.2020.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
109 Multhoff G, Radons J. Radiation, inflammation, and immune responses in cancer. Front Oncol. 2012;2:58. [PMID: 22675673 DOI: 10.3389/fonc.2012.00058] [Cited by in Crossref: 86] [Cited by in F6Publishing: 103] [Article Influence: 8.6] [Reference Citation Analysis]
110 Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112-127. [PMID: 33235387 DOI: 10.1038/s41423-020-00572-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
111 Dinić M, Lukić J, Djokić J, Milenković M, Strahinić I, Golić N, Begović J. Lactobacillus fermentum Postbiotic-induced Autophagy as Potential Approach for Treatment of Acetaminophen Hepatotoxicity. Front Microbiol 2017;8:594. [PMID: 28428777 DOI: 10.3389/fmicb.2017.00594] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
112 Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem. 2013;59:155-201. [PMID: 23461136 DOI: 10.1016/b978-0-12-405211-6.00006-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
113 Federico A, Dallio M, Godos J, Loguercio C, Salomone F. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res. 2016;167:116-124. [PMID: 26318867 DOI: 10.1016/j.trsl.2015.08.002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
114 Toffanin S, Cornella H, Harrington A, Llovet JM. HCC Is promoted by bacterial translocation and TLR-4 signaling: a new paradigm for chemoprevention and management. Hepatology 2012;56:1998-2000. [PMID: 23115011 DOI: 10.1002/hep.26080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
115 Zhang S, Wang Z, Zhu J, Xu T, Zhao Y, Zhao H, Tang F, Li Z, Zhou J, Gao D, Tian X, Yao J. Carnosic Acid Alleviates BDL-Induced Liver Fibrosis through miR-29b-3p-Mediated Inhibition of the High-Mobility Group Box 1/Toll-Like Receptor 4 Signaling Pathway in Rats. Front Pharmacol 2017;8:976. [PMID: 29403377 DOI: 10.3389/fphar.2017.00976] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
116 Ceccarelli S, Nobili V, Alisi A. Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. World J Gastroenterol 2014; 20(44): 16443-16451 [PMID: 25469012 DOI: 10.3748/wjg.v20.i44.16443] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
117 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 64-85. [DOI: 10.1016/b978-1-4377-0881-3.00005-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
118 Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108-18. [PMID: 21293511 DOI: 10.1038/nrgastro.2010.213] [Cited by in Crossref: 673] [Cited by in F6Publishing: 667] [Article Influence: 61.2] [Reference Citation Analysis]
119 Singh A, Garg R, Lan N, Siddiqui MT, Gupta M, Alkhouri N. Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:591-8. [DOI: 10.1007/s12664-020-01087-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Garcia-Martinez I, Shaker ME, Mehal WZ. Therapeutic Opportunities in Damage-Associated Molecular Pattern-Driven Metabolic Diseases. Antioxid Redox Signal 2015;23:1305-15. [PMID: 26055926 DOI: 10.1089/ars.2015.6383] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
121 Chou MH, Huang YH, Lin TM, Du YY, Tsai PC, Hsieh CS, Chuang JH. Selective activation of Toll-like receptor 7 in activated hepatic stellate cells may modulate their profibrogenic phenotype. Biochem J 2012;447:25-34. [PMID: 22765640 DOI: 10.1042/BJ20112058] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
122 Spengler ML, Kuropatwinski KK, Comas M, Gasparian AV, Fedtsova N, Gleiberman AS, Gitlin II, Artemicheva NM, Deluca KA, Gudkov AV, Antoch MP. Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription. Proc Natl Acad Sci U S A 2012;109:E2457-65. [PMID: 22895791 DOI: 10.1073/pnas.1206274109] [Cited by in Crossref: 187] [Cited by in F6Publishing: 177] [Article Influence: 18.7] [Reference Citation Analysis]
123 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2021. [PMID: 34564899 DOI: 10.1111/joim.13380] [Reference Citation Analysis]
124 Li X, Shen J, Ran Z. Crosstalk between the gut and the liver via susceptibility loci: Novel advances in inflammatory bowel disease and autoimmune liver disease. Clinical Immunology 2017;175:115-23. [DOI: 10.1016/j.clim.2016.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
125 Bigorgne AE, John B, Ebrahimkhani MR, Shimizu-Albergine M, Campbell JS, Crispe IN. TLR4-Dependent Secretion by Hepatic Stellate Cells of the Neutrophil-Chemoattractant CXCL1 Mediates Liver Response to Gut Microbiota. PLoS One 2016;11:e0151063. [PMID: 27002851 DOI: 10.1371/journal.pone.0151063] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
126 Shirai Y, Yoshiji H, Noguchi R, Kaji K, Aihara Y, Douhara A, Moriya K, Namisaki T, Kawaratani H, Fukui H. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2013;28:723-730. [PMID: 23301938 DOI: 10.1111/jgh.12112] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
127 Seledtsov VI, Goncharov AG, Seledtsova GV. Clinically feasible approaches to potentiating cancer cell-based immunotherapies. Hum Vaccin Immunother 2015;11:851-69. [PMID: 25933181 DOI: 10.1080/21645515.2015.1009814] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
128 Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. World J Gastroenterol 2012; 18(46): 6693-6700 [PMID: 23239905 DOI: 10.3748/wjg.v18.i46.6693] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
129 Breous E, Somanathan S, Bell P, Wilson JM. Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology 2011;141:348-57, 357.e1-3. [PMID: 21640112 DOI: 10.1053/j.gastro.2011.04.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
130 Neves AL, Coelho J, Couto L, Leite-Moreira A, Roncon-Albuquerque R Jr. Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J Mol Endocrinol 2013;51:R51-64. [PMID: 23943858 DOI: 10.1530/JME-13-0079] [Cited by in Crossref: 111] [Cited by in F6Publishing: 57] [Article Influence: 12.3] [Reference Citation Analysis]
131 Benedé-Ubieto R, Estévez-Vázquez O, Guo F, Chen C, Singh Y, Nakaya HI, Gómez Del Moral M, Lamas-Paz A, Morán L, López-Alcántara N, Reissing J, Bruns T, Avila MA, Santamaría E, Mazariegos MS, Woitok MM, Haas U, Zheng K, Juárez I, Martín-Villa JM, Asensio I, Vaquero J, Peligros MI, Argemi J, Bataller R, Ampuero J, Romero Gómez M, Trautwein C, Liedtke C, Bañares R, Cubero FJ, Nevzorova YA. An Experimental DUAL Model of Advanced Liver Damage. Hepatol Commun 2021;5:1051-68. [PMID: 34141989 DOI: 10.1002/hep4.1698] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Tutunchi H, Ostadrahimi A, Saghafi-Asl M, Roshanravan N, Shakeri-Bavil A, Asghari-Jafarabadi M, Farrin N, Mobasseri M. Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial. J Cell Physiol 2021;236:417-26. [PMID: 32572955 DOI: 10.1002/jcp.29870] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
133 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412-425. [PMID: 27273168 DOI: 10.1038/nrgastro.2016.85] [Cited by in Crossref: 362] [Cited by in F6Publishing: 339] [Article Influence: 60.3] [Reference Citation Analysis]
134 Sun X, Liu J, Xu C, Tang SC, Ren H. The insights of Let-7 miRNAs in oncogenesis and stem cell potency. J Cell Mol Med. 2016;20:1779-1788. [PMID: 27097729 DOI: 10.1111/jcmm.12861] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
135 Hu X, Wang T, Liang S, Li W, Wu X, Jin F. Antibiotic-induced imbalances in gut microbiota aggravates cholesterol accumulation and liver injuries in rats fed a high-cholesterol diet. Appl Microbiol Biotechnol 2015;99:9111-22. [PMID: 26129950 DOI: 10.1007/s00253-015-6753-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
136 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-638. [PMID: 24830559 DOI: 10.3390/ijms15058591] [Cited by in Crossref: 178] [Cited by in F6Publishing: 164] [Article Influence: 22.3] [Reference Citation Analysis]
137 Shalini V, Jayalekshmi A, Helen A. Mechanism of anti-inflammatory effect of tricin, a flavonoid isolated from Njavara rice bran in LPS induced hPBMCs and carrageenan induced rats. Mol Immunol 2015;66:229-39. [PMID: 25839778 DOI: 10.1016/j.molimm.2015.03.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
138 Marongiu L, Landry JJM, Rausch T, Abba ML, Delecluse S, Delecluse HJ, Allgayer H. Metagenomic analysis of primary colorectal carcinomas and their metastases identifies potential microbial risk factors. Mol Oncol 2021. [PMID: 34328665 DOI: 10.1002/1878-0261.13070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Cengiz M, Ozenirler S, Elbeg S. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol. 2015;30:1190-1196. [PMID: 25684563 DOI: 10.1111/jgh.12924] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
140 Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:246-58. [PMID: 29105111 DOI: 10.1111/apt.14391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
141 Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627-636. [PMID: 23958599 DOI: 10.1038/nrgastro.2013.149] [Cited by in Crossref: 335] [Cited by in F6Publishing: 320] [Article Influence: 37.2] [Reference Citation Analysis]
142 Ya P, Xu H, Ma Y, Fang M, Yan X, Zhou J, Li F. Liver injury induced in Balb/c mice by PM2.5 exposure and its alleviation by compound essential oils. Biomedicine & Pharmacotherapy 2018;105:590-8. [DOI: 10.1016/j.biopha.2018.06.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
143 Foulds GA, Radons J, Kreuzer M, Multhoff G, Pockley AG. Influence of tumors on protective anti-tumor immunity and the effects of irradiation. Front Oncol 2013;3:14. [PMID: 23378947 DOI: 10.3389/fonc.2013.00014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
144 Wang L, Zhang W, Ge CH, Yin RH, Xiao Y, Zhan YQ, Yu M, Li CY, Ge ZQ, Yang XM. Toll-like receptor 5 signaling restrains T-cell/natural killer T-cell activation and protects against concanavalin A-induced hepatic injury. Hepatology 2017;65:2059-73. [PMID: 28273362 DOI: 10.1002/hep.29140] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
145 Jiang N, Zhang X, Zheng X, Chen D, Zhang Y, Siu LK, Xin HB, Li R, Zhao H, Riordan N. Targeted gene silencing of TLR4 using liposomal nanoparticles for preventing liver ischemia reperfusion injury. Am J Transplant. 2011;11:1835-1844. [PMID: 21794086 DOI: 10.1111/j.1600-6143.2011.03660.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
146 Kessoku T, Imajo K, Kobayashi T, Honda Y, Kato T, Ogawa Y, Tomeno W, Kato S, Higurashi T, Yoneda M, Kirikoshi H, Kubota K, Taguri M, Yamanaka T, Usuda H, Wada K, Saito S, Nakajima A. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. Contemporary Clinical Trials 2018;69:40-7. [DOI: 10.1016/j.cct.2018.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
147 Guo J, Friedman SL. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair. 2010;3:21. [PMID: 20964825 DOI: 10.1186/1755-1536-3-21] [Cited by in Crossref: 172] [Cited by in F6Publishing: 164] [Article Influence: 14.3] [Reference Citation Analysis]
148 Sehgal R, Bedi O, Trehanpati N. Role of Microbiota in Pathogenesis and Management of Viral Hepatitis.Front Cell Infect Microbiol. 2020;10:341. [PMID: 32850467 DOI: 10.3389/fcimb.2020.00341] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
149 Petrasek J, Dolganiuc A, Csak T, Nath B, Hritz I, Kodys K, Catalano D, Kurt-Jones E, Mandrekar P, Szabo G. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology. 2011;53:649-660. [PMID: 21274885 DOI: 10.1002/hep.24059] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 6.3] [Reference Citation Analysis]
150 Pierantonelli I, Rychlicki C, Agostinelli L, Giordano DM, Gaggini M, Fraumene C, Saponaro C, Manghina V, Sartini L, Mingarelli E. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. Sci Rep. 2017;7:12200. [PMID: 28939830 DOI: 10.1038/s41598-017-11744-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
151 Howell J, Gow P, Angus P, Visvanathan K. Role of toll-like receptors in liver transplantation. Liver Transpl. 2014;20:270-280. [PMID: 24243591 DOI: 10.1002/lt.23793] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
152 Singh A, Koduru B, Carlisle C, Akhter H, Liu RM, Schroder K, Brandes RP, Ojcius DM. NADPH oxidase 4 modulates hepatic responses to lipopolysaccharide mediated by Toll-like receptor-4. Sci Rep 2017;7:14346. [PMID: 29085012 DOI: 10.1038/s41598-017-14574-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
153 Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. Curr Opin Oncol 2014;26:100-7. [PMID: 24275855 DOI: 10.1097/CCO.0000000000000042] [Cited by in Crossref: 60] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
154 Wang Y, Liu Y, Sidhu A, Ma Z, McClain C, Feng W. Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury. Am J Physiol Gastrointest Liver Physiol. 2012;303:G32-G41. [PMID: 22538402 DOI: 10.1080/07315724.2012.10720004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
155 Ballway JW, Song BJ. Translational Approaches with Antioxidant Phytochemicals against Alcohol-Mediated Oxidative Stress, Gut Dysbiosis, Intestinal Barrier Dysfunction, and Fatty Liver Disease. Antioxidants (Basel) 2021;10:384. [PMID: 33806556 DOI: 10.3390/antiox10030384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
156 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
157 Howell J, Angus P, Gow P, Visvanathan K. Toll-like receptors in hepatitis C infection: Implications for pathogenesis and treatment: Toll-like receptors in hepatitis C. J Gastroenterol Hepatol 2013;28:766-76. [DOI: 10.1111/jgh.12170] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
158 Leroux A, Ferrere G, Godie V, Cailleux F, Renoud ML, Gaudin F, Naveau S, Prévot S, Makhzami S, Perlemuter G, Cassard-Doulcier AM. Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis. J Hepatol 2012;57:141-9. [PMID: 22425624 DOI: 10.1016/j.jhep.2012.02.028] [Cited by in Crossref: 138] [Cited by in F6Publishing: 129] [Article Influence: 13.8] [Reference Citation Analysis]
159 Ganousse-Mazeron S, Lacaille F, Colomb-Jung V, Talbotec C, Ruemmele F, Sauvat F, Chardot C, Canioni D, Jan D, Revillon Y. Assessment and outcome of children with intestinal failure referred for intestinal transplantation. Clin Nutr. 2015;34:428-435. [PMID: 25015836 DOI: 10.1016/j.clnu.2014.04.015] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
160 Kim MS, Ong M, Qu X. Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? World J Gastroenterol 2016; 22(1): 8-23 [PMID: 26755857 DOI: 10.3748/wjg.v22.i1.8] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
161 Zhao C, Cui X, Zhao Y, Qian B, Zhang N, Xin L, Ha C, Yang J, Wang X, Gao X. Impact of hepatocyte-specific deletion of staphylococcal nuclease and tudor domain containing 1 (SND1) on liver insulin resistance and acute liver failure of mice. Bioengineered 2021;12:7360-75. [PMID: 34608846 DOI: 10.1080/21655979.2021.1974653] [Reference Citation Analysis]
162 Friedman SL. Hepatic Fibrosis. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 295-315. [DOI: 10.1002/9781119950509.ch12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
164 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
165 Kim MY. [The Progression of Liver Fibrosis in Non-alcoholic Fatty Liver Disease]. Korean J Gastroenterol 2017;69:341-7. [PMID: 28637102 DOI: 10.4166/kjg.2017.69.6.341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
166 Xiao X, Zhao P, Rodriguez-Pinto D, Qi D, Henegariu O, Alexopoulou L, Flavell RA, Wong FS, Wen L. Inflammatory regulation by TLR3 in acute hepatitis. J Immunol 2009;183:3712-9. [PMID: 19710451 DOI: 10.4049/jimmunol.0901221] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
167 Peng JL, Techasatian W, Hato T, Liangpunsakul S. Role of endotoxemia in causing renal dysfunction in cirrhosis. J Investig Med 2020;68:26-9. [PMID: 31324695 DOI: 10.1136/jim-2019-001056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
168 Hendrikx T, Schnabl B. Antimicrobial proteins: intestinal guards to protect against liver disease. J Gastroenterol 2019;54:209-17. [PMID: 30392013 DOI: 10.1007/s00535-018-1521-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
169 Nieto JC, Sánchez E, Román E, Vidal S, Oliva L, Guarner-Argente C, Poca M, Torras X, Juárez C, Guarner C, Soriano G. Cytokine production in patients with cirrhosis and TLR4 polymorphisms. World J Gastroenterol 2014; 20(46): 17516-17524 [PMID: 25516666 DOI: 10.3748/wjg.v20.i46.17516] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
170 Xie YR, Liu SL, Liu X, Luo ZB, Zhu B, Li ZF, Li LJ, He Y, Jiang L, Li H. Intestinal microbiota and innate immunity-related gene alteration in cirrhotic rats with liver transplantation. Transplant Proc. 2011;43:3973-3979. [PMID: 22172882 DOI: 10.1016/j.transproceed.2011.08.113] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
171 Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco C, Loguercio C. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis. 2011;43:431-438. [PMID: 21163715 DOI: 10.1016/j.dld.2010.10.015] [Cited by in Crossref: 104] [Cited by in F6Publishing: 100] [Article Influence: 8.7] [Reference Citation Analysis]
172 Youssef SS, Hamdy NM. SOCS1 and pattern recognition receptors: TLR9 and RIG-I; novel haplotype associations in Egyptian fibrotic/cirrhotic patients with HCV genotype 4. Arch Virol 2017;162:3347-54. [PMID: 28762092 DOI: 10.1007/s00705-017-3498-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
173 Ajamieh H, Farrell G, Wong HJ, Yu J, Chu E, Chen J, Teoh N. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation. J Gastroenterol Hepatol. 2012;27:1353-1361. [PMID: 22432744 DOI: 10.1111/j.1440-1746.2012.07123.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
174 Liu Z, Zhang Z, Huang M, Sun X, Liu B, Guo Q, Chang Q, Duan Z. Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments. BMC Gastroenterol 2018;18:112. [PMID: 29996772 DOI: 10.1186/s12876-018-0842-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
175 Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond). 2012;122:545-553. [PMID: 22142284 DOI: 10.1042/cs20110366] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
176 Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013;3:785-797. [PMID: 23720329 DOI: 10.1002/cphy.c120026] [Cited by in Crossref: 90] [Cited by in F6Publishing: 171] [Article Influence: 10.0] [Reference Citation Analysis]
177 Zahran AM, Zahran ZAM, El-Badawy O, Abdel-Rahim MH, Ali WAM, Rayan A, Abbas El-Masry M, Abozaid MAA, Hetta HF. Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma. Immunol Res 2019;67:157-65. [PMID: 31028612 DOI: 10.1007/s12026-019-09075-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
178 Abdel-raouf TA, Ahmed A, Zaki WK, Abdella HM, Zid MA. Study of toll-like receptor 7 expression and interferon α in Egyptian patients with chronic hepatitis C Infection and Hepatocellular Carcinoma. Egyptian Journal of Medical Human Genetics 2014;15:387-92. [DOI: 10.1016/j.ejmhg.2014.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
179 Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol. 2013;28 Suppl 1:77-84. [PMID: 23855300 DOI: 10.1111/jgh.12030] [Cited by in Crossref: 144] [Cited by in F6Publishing: 138] [Article Influence: 18.0] [Reference Citation Analysis]
180 Gan Z, Wei W, Li Y, Wu J, Zhao Y, Zhang L, Wang T, Zhong X. Curcumin and Resveratrol Regulate Intestinal Bacteria and Alleviate Intestinal Inflammation in Weaned Piglets. Molecules 2019;24:E1220. [PMID: 30925757 DOI: 10.3390/molecules24071220] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
181 Scheuermann U, Zhu M, Song M, Yerxa J, Gao Q, Davis RP, Zhang M, Parker W, Hartwig MG, Kwun J, Brennan TV, Lee J, Barbas AS. Damage-Associated Molecular Patterns Induce Inflammatory Injury During Machine Preservation of the Liver: Potential Targets to Enhance a Promising Technology. Liver Transpl. 2019;. [PMID: 30734488 DOI: 10.1002/lt.25429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
182 Xu P, Zhang Y, Liu Y, Yuan Q, Song L, Liu M, Liu Z, Yang Y, Li J, Li D, Ren G. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-β/smad2/3 and NF-κB signaling pathways. Toxicol Appl Pharmacol 2016;290:43-53. [PMID: 26592322 DOI: 10.1016/j.taap.2015.11.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
183 Rosselli M, MacNaughtan J, Jalan R, Pinzani M. Beyond scoring: a modern interpretation of disease progression in chronic liver disease. Gut 2013;62:1234-41. [PMID: 23645629 DOI: 10.1136/gutjnl-2012-302826] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
184 Yang M, Xiao Z, Lv Q, Liu X, Zhou L, Chen X, Chen M, Fang L, Xie X, Hu J. The functional expression of TLR3 in EPCs impairs cell proliferation by induction of cell apoptosis and cell cycle progress inhibition. Int Immunopharmacol 2011;11:2118-24. [PMID: 21964048 DOI: 10.1016/j.intimp.2011.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
185 Ji L, Xue R, Tang W, Wu W, Hu T, Liu X, Peng X, Gu J, Chen S, Zhang S. Toll like receptor 2 knock-out attenuates carbon tetrachloride (CCl4)-induced liver fibrosis by downregulating MAPK and NF-κB signaling pathways. FEBS Lett. 2014;588:2095-2100. [PMID: 24815695 DOI: 10.1016/j.febslet.2014.04.042] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
186 Zhang HL, Yu LX, Yang W, Tang L, Lin Y, Wu H, Zhai B, Tan YX, Shan L, Liu Q. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J Hepatol. 2012;57:803-812. [PMID: 22727732 DOI: 10.1016/j.jhep.2012.06.011] [Cited by in Crossref: 127] [Cited by in F6Publishing: 124] [Article Influence: 12.7] [Reference Citation Analysis]
187 Hu S, Ghabril M, Amet T, Hu N, Byrd D, Yang K, Vuppalanchi R, Saxena R, Desai M, Lan J, Johnson R, Gupta S, Chalasani N, Yu Q. HIV-1 coinfection profoundly alters intrahepatic chemokine but not inflammatory cytokine profiles in HCV-infected subjects. PLoS One 2014;9:e86964. [PMID: 24516541 DOI: 10.1371/journal.pone.0086964] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
188 Gelman MA, Glenn JS. Mixing the right hepatitis C inhibitor cocktail. Trends Mol Med. 2010;Epub ahead of print. [PMID: 21106440 DOI: 10.1016/j.molmed.2010.10.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
189 Li W, Xiao J, Zhou X, Xu M, Hu C, Xu X, Lu Y, Liu C, Xue S, Nie L, Zhang H, Li Z, Zhang Y, Ji F, Hui L, Tao W, Wei B, Wang H. STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma. J Clin Invest 2015;125:4239-54. [PMID: 26457732 DOI: 10.1172/JCI81203] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
190 Lee Y, Friedman SL. Fibrosis in the Liver. Development, Differentiation and Disease of the Para-Alimentary Tract. Elsevier; 2010. pp. 151-200. [DOI: 10.1016/b978-0-12-385233-5.00006-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
191 Mann DA, Marra F. Fibrogenic signalling in hepatic stellate cells. Journal of Hepatology 2010;52:949-50. [DOI: 10.1016/j.jhep.2010.02.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
192 Alisi A, Carsetti R, Nobili V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology 2011;54:1500-2. [DOI: 10.1002/hep.24611] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
193 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
194 McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mamm Genome 2018;29:843-65. [PMID: 30178305 DOI: 10.1007/s00335-018-9777-0] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 13.5] [Reference Citation Analysis]
195 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013;19:5250-69. [PMID: 23394092 DOI: 10.2174/13816128113199990344] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 11.8] [Reference Citation Analysis]
196 Wang K, Wei H, Zhan J, Liang X, Zhang C, Liu Y, Xu G. GSPE alleviates renal fibrosis by inhibiting the activation of C3/ HMGB1/ TGF-β1 pathway. Chem Biol Interact 2020;316:108926. [PMID: 31874164 DOI: 10.1016/j.cbi.2019.108926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
197 Seledtsov V, Seledtsova G. A balance between tissue-destructive and tissue-protective immunities: A role of toll-like receptors in regulation of adaptive immunity. Immunobiology 2012;217:430-5. [DOI: 10.1016/j.imbio.2011.10.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
198 Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, Tanaka T, Arai M, Fujiwara K, Saito K, Roger T. Hepatitis C Virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis. 2011;204:793-801. [PMID: 21844306 DOI: 10.1093/infdis/jir381] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
199 Guarner-Argente C, Sánchez E, Vidal S, Román E, Concepción M, Poca M, Sánchez D, Juárez C, Soriano G, Guarner C. Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients. Aliment Pharmacol Ther. 2010;31:1192-1199. [PMID: 20222908 DOI: 10.1111/j.1365-2036.2010.04291.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
200 Eguchi A, Iwasa M, Tamai Y, Tempaku M, Takamatsu S, Miyoshi E, Hasegawa H, Kobayashi Y, Takei Y. Branched-chain amino acids protect the liver from cirrhotic injury via suppression of activation of lipopolysaccharide-binding protein, toll-like receptor 4, and signal transducer and activator of transcription 3, as well as Enterococcus faecalis translocation. Nutrition 2021;86:111194. [PMID: 33743328 DOI: 10.1016/j.nut.2021.111194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Wiggers JK, van Golen RF, Verheij J, Dekker AM, van Gulik TM, Heger M. Atorvastatin does not protect against ischemia-reperfusion damage in cholestatic rat livers. BMC Surg 2017;17:35. [PMID: 28399849 DOI: 10.1186/s12893-017-0235-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
202 Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13:88-110. [PMID: 26758786 DOI: 10.1038/nrgastro.2015.200] [Cited by in Crossref: 425] [Cited by in F6Publishing: 405] [Article Influence: 70.8] [Reference Citation Analysis]
203 Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol 2016;311:G1018-36. [PMID: 27686615 DOI: 10.1152/ajpgi.00245.2016] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
204 Qu BG. Inflammatory and immune changes and treatment in patients with fatty liver disease. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2931-2942 [DOI: 10.11569/wcjd.v24.i19.2931] [Reference Citation Analysis]
205 Pinzani M, Macias-Barragan J. Update on the pathophysiology of liver fibrosis. Expert Rev Gastroenterol Hepatol 2010;4:459-72. [PMID: 20678019 DOI: 10.1586/egh.10.47] [Cited by in Crossref: 79] [Cited by in F6Publishing: 79] [Article Influence: 6.6] [Reference Citation Analysis]
206 Ren X, Wang F, Ji B, Gao C. TLR7 agonist induced repression of hepatocellular carcinoma via the TLR7-IKK-NF-κB-IL6 signaling pathway. Oncol Lett 2016;11:2965-70. [PMID: 27123047 DOI: 10.3892/ol.2016.4329] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
207 Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141:1572-1585. [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002] [Cited by in Crossref: 1046] [Cited by in F6Publishing: 1007] [Article Influence: 95.1] [Reference Citation Analysis]
208 Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown ZJ, Wabitsch S, Thovarai V, Fu J, Feng D, Ruf B, Cui LL, Subramanyam V, Frank KM, Wang S, Kleiner DE, Ritz T, Rupp C, Gao B, Longerich T, Kroemer A, Wang XW, Ruchirawat M, Korangy F, Schnabl B, Trinchieri G, Greten TF. Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discov 2021;11:1248-67. [PMID: 33323397 DOI: 10.1158/2159-8290.CD-20-0304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
209 Harvey SA, Dangi A, Tandon A, Gandhi CR. The transcriptomic response of rat hepatic stellate cells to endotoxin: implications for hepatic inflammation and immune regulation. PLoS One. 2013;8:e82159. [PMID: 24349206 DOI: 10.1371/journal.pone.0082159] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
210 Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab 2010;21:707-13. [PMID: 20888782 DOI: 10.1016/j.tem.2010.08.010] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 6.3] [Reference Citation Analysis]
211 Ajoolabady A, Aslkhodapasandhokmabad H, Zhou Y, Ren J. Epigenetic modification in alcohol‐related liver diseases. Medicinal Research Reviews. [DOI: 10.1002/med.21881] [Reference Citation Analysis]
212 Amiresmaili S, Khaksari M, Shahrokhi N, Abolhassani M. Evolution of TLR4 role in mediating the hepatoprotective effects of estradiol after traumatic brain injury in male rats. Biochem Pharmacol 2020;178:114044. [PMID: 32445868 DOI: 10.1016/j.bcp.2020.114044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
213 Jia R, Cao LP, Du JL, He Q, Gu ZY, Jeney G, Xu P, Yin GJ. Effects of high-fat diet on antioxidative status, apoptosis and inflammation in liver of tilapia (Oreochromis niloticus) via Nrf2, TLRs and JNK pathways. Fish Shellfish Immunol 2020;104:391-401. [PMID: 32553566 DOI: 10.1016/j.fsi.2020.06.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
214 Li N, Chen MQ, Qian ZP, Zhu MQ, Li Q, Zheng JM, Wang XY, Shi GF. Correlation of the expression of toll-like receptors in monocyte-derived dendritic cells with prognosis of chronic severe hepatitis B: TLR expression in MoDC with CSHB. Journal of Digestive Diseases 2011;12:117-24. [DOI: 10.1111/j.1751-2980.2011.00486.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
215 Marra F, Aleffi S, Galastri S, Provenzano A. Mononuclear cells in liver fibrosis. Semin Immunopathol. 2009;31:345-358. [PMID: 19533130 DOI: 10.1007/s00281-009-0169-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 5.4] [Reference Citation Analysis]
216 Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease. J Hepatol. 2012;57:897-909. [PMID: 22634121 DOI: 10.1016/j.jhep.2012.04.033] [Cited by in Crossref: 134] [Cited by in F6Publishing: 121] [Article Influence: 13.4] [Reference Citation Analysis]
217 Wang X, Ji D, Zhu B, Jiang S, Han L, Wang Y, Mai H, Xu S, Jiang H, Wang G, Rong Y. Contribution of endotoxin to Th17 bias in patients with non-alcoholic steatohepatitis. Microb Pathog 2020;142:104009. [PMID: 32001302 DOI: 10.1016/j.micpath.2020.104009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Petrasek J, Dolganiuc A, Csak T, Kurt-Jones EA, Szabo G. Type I interferons protect from Toll-like receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology. 2011;140:697-708.e4. [PMID: 20727895 DOI: 10.1053/j.gastro.2010.08.020] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
219 Lai FB, Liu WT, Jing YY, Yu GF, Han ZP, Yang X, Zeng JX, Zhang HJ, Shi RY, Li XY, Pan XR, Li R, Zhao QD, Wu MC, Zhang P, Liu JF, Wei LX. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway. Cancer Lett 2016;378:131-41. [PMID: 27208741 DOI: 10.1016/j.canlet.2016.05.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
220 Chen MY, Yadav VK, Chu YC, Ong JR, Huang TY, Lee KF, Lee KH, Yeh CT, Lee WH. Hydroxychloroquine (HCQ) Modulates Autophagy and Oxidative DNA Damage Stress in Hepatocellular Carcinoma to Overcome Sorafenib Resistance via TLR9/SOD1/hsa-miR-30a-5p/Beclin-1 Axis. Cancers (Basel) 2021;13:3227. [PMID: 34203465 DOI: 10.3390/cancers13133227] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev. 2011;CD008716. [PMID: 22071855 DOI: 10.1002/14651858.cd008716.pub2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
222 Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012;51:305-312. [PMID: 22999829 DOI: 10.1016/j.jadohealth.2012.01.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
223 Yin S, Gao B. Toll-like receptor 3 in liver diseases. Gastroenterol Res Pract. 2010;2010. [PMID: 20936107 DOI: 10.1155/2010/750904] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
224 Kairaluoma V, Kemi N, Huhta H, Pohjanen V, Helminen O. Prognostic role of TLR4 and TLR2 in hepatocellular carcinoma. Acta Oncologica 2021;60:554-8. [DOI: 10.1080/0284186x.2021.1877346] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Zhou Y, Zhang P, Zheng X, Ye C, Li M, Bian P, Fan C, Zhang Y. miR-155 regulates pro- and anti-inflammatory cytokine expression in human monocytes during chronic hepatitis C virus infection. Ann Transl Med 2021;9:1618. [PMID: 34926662 DOI: 10.21037/atm-21-2620] [Reference Citation Analysis]
226 Mohamed FE, Al-Jehani RM, Minogue SS, Andreola F, Winstanley A, Olde Damink SW, Habtesion A, Malagó M, Davies N, Luong TV. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015;35:1063-1076. [PMID: 24990399 DOI: 10.1111/liv.12626] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
227 Cavassani KA, Moreira AP, Habiel D, Ito T, Coelho AL, Allen RM, Hu B, Raphelson J, Carson WF 4th, Schaller MA, Lukacs NW, Omary MB, Hogaboam CM, Kunkel SL. Toll like receptor 3 plays a critical role in the progression and severity of acetaminophen-induced hepatotoxicity. PLoS One 2013;8:e65899. [PMID: 23762449 DOI: 10.1371/journal.pone.0065899] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
228 Nakamoto N, Kanai T. Role of toll-like receptors in immune activation and tolerance in the liver. Front Immunol. 2014;5:221. [PMID: 24904576 DOI: 10.3389/fimmu.2014.00221] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 9.0] [Reference Citation Analysis]
229 Fletcher NF, Sutaria R, Jo J, Barnes A, Blahova M, Meredith LW, Cosset FL, Curbishley SM, Adams DH, Bertoletti A. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology. 2014;59:1320-1330. [PMID: 24259385 DOI: 10.1002/hep.26911] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
230 Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients. 2011;3:637-682. [PMID: 22254115 DOI: 10.3390/nu3060637] [Cited by in Crossref: 217] [Cited by in F6Publishing: 195] [Article Influence: 19.7] [Reference Citation Analysis]
231 Al-Qahtani A, Al-Ahdal M, Abdo A, Sanai F, Al-Anazi M, Khalaf N, Viswan NA, Al-Ashgar H, Al-Humaidan H, Al-Suwayeh R. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. J Med Virol. 2012;84:1353-1359. [PMID: 22825813 DOI: 10.1002/jmv.23271] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]